menu

ReachMD

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Revolutionary Approaches to Improving Outcomes in Unresected LA SCCHN

Are you and your team incorporating the latest data on unresected locally advanced squamous cell carcinoma of the head and neck into practice?

Live Meeting
1.00 available credits
Information
October 2, 2023
06:30 PM - 07:30 PM PDT
Manchester Grand Hyatt San Diego
1 Market Place, Room: Seaport Ballroom AB, San Diego, California, United States
ReachMD Healthcare Image
Details
Presenters
Related
Comments
  • Overview

    Join our international multidisciplinary panel of experts in exploring revolutionary approaches to treating patients with unresectable locally advanced squamous cell carcinoma of the head and neck and dinner. Through engaging presentations and discussions, the panel will address key aspects of patient management including new and emerging therapies, the clinical significance of early endpoints used in clinical trials, and future directions in treatment.

  • Program Schedule

    Times listed in Pacific Daylight Time

    6:15pm – 6:30pm   Doors Open, Registration, and Dinner
    6:30pm – 6:33pm   Welcome and Introductions
    6:33pm – 6:37pm   Overview of LA SCCHN
    6:37pm – 6:47pm   Current Landscape in LA SCCHN
    6:47pm – 6:59pm   Raising Awareness of Emerging Evidence in LA SCCHN
    6:59pm – 7:11pm    A Comprehensive Analysis of IAPs
    7:11pm – 7:20pm    Understanding Clinical Trials and Their Endpoints in LA SCCHN
    7:20pm – 7:30pm   Question and Answer Session

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Host:
    Ezra Cohen, MD, FRCPSC, FASCO
    Chief Medical Officer, Oncology
    Tempus Labs
    Professor of Medicine, Division of Hematology/Oncology
    University of California San Diego Health
    San Diego, CA, US

    Consulting Fees: Adagene, Astellas, Cidara, Eisai, Genmab, Gilboa, iTeos, Lilly, MSD, Merck, Nectin Tx, Novartis, Nykode, Pangea Therapeutics, PCI Biotech, Replimune, Roche, Soteria, Tempus, Viracta
    Employee of an ineligible company: Tempus Labs
    Ownership Interest: Kinnate Biopharma, Primmune Therapeutics
    Research: NCI

    Faculty:
    Kevin J Harrington, PhD, FRCP, FRCR, FRSB
    Professor in Biological Cancer Therapies
    The Institute of Cancer Research
    London UK

    Consulting Fees: AstraZeneca, Boehringer Ingelheim, Merck, MSD, Replimune
    Research: AstraZeneca, Boehringer Ingelheim, Replimune

    Deborah J. Wong, MD, PhD
    Associate Clinical Professor of Medicine
    David Geffen School of Medicine
    University of California, Los Angeles
    Los Angeles, CA, US

    Consulting Fees: MSD
    Research: AstraZeneca, BICARA Therapeutics, Bristol-Myers Squibb Company, FSTAR Therapeutics, Genentech, Gilead, KURA Oncology, Lilly, MSD, Pfizer, Regeneron, TopAlliance

    Reviewers/Content Planners/Authors:

    • Jorge Bacigalupo has nothing to disclose.
    • Cindy Davidson has nothing to disclose.
    • Ann Early has nothing to disclose
    • Robert Giest, MD, has nothing to disclose.
    • Andrea Mathis has nothing to disclose.
    • Tim Person has nothing to disclose.
    • Rosanne Strauss PharmD, MBA, has nothing to disclose.
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Identify the various factors that contribute to the recurrence or progression of locally advanced squamous cell carcinoma of the head and neck (SCCHN)
    • Evaluate the risks, benefits, and limitations of currently available treatment options for managing patients with locally advanced SCCHN, and develop a comprehensive management plan based on patient-specific factors
    • Discuss the mechanisms of action of agents currently under investigation for the treatment of locally advanced SCCHN alongside those of currently available treatment options, and potential implications for patient care
    • Assess the therapeutic potential and potential impact on current treatment paradigms of emerging agents being investigated for the management of locally advanced SCCHN
    • Compare the definitions, benefits, and limitations of early endpoints used in oncology trials and their relation to patient outcomes
    • Describe the evidence, rationale, and clinical significance of early endpoints used in ongoing clinical trials in locally advanced SCCHN
  • Target Audience

    This activity is designed to meet the educational needs of medical oncologists, radiation oncologists, pathologists, and other healthcare professional treating patients with head and neck cancers in the United States.

  • Accreditation and Credit Designation Statements

    In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

    Global Learning Collaborative (GLC) designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) designates this activity for 1.0 nursing contact hours. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

  • Provider(s)/Educational Partner(s)

    Prova Education designs and executes continuing education founded on evidence-based medicine, clinical need, gap analysis, learner feedback, and more. Our mission is to serve as an inventive and relevant resource for clinical content and educational interventions across a broad spectrum of specialties.

    Prova Education's methodology demonstrates a commitment to continuing medical education and the innovative assessment of its effects. Our goal is clear—to develop and deliver the very best education in the most impactful manner and to verify its results with progressive outcomes research. 

  • Commercial Support

    This activity is supported by an independent educational grant from EMD Serono, Inc. EMD Serono, Inc. is the Healthcare business of Merck KGaA, Darmstadt, Germany.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Prova Education. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to access a site outside of Prova Education you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited
    Reproduction of this material is not permitted without written permission from the copyright owner.

  • ADA Statement

    Event staff will be glad to assist you with any special needs (eg, physical, dietary, etc.). Please contact Andrea Mathis prior to the live event at amathis@glc.healthcare.

  • System Requirements

    • Supported Browsers (2 most recent versions):
      • Google Chrome for Windows, Mac OS, iOS, and Android
      • Apple Safari for Mac OS and iOS
      • Mozilla Firefox for Windows, Mac OS, iOS, and Android
      • Microsoft Edge for Windows
    • Recommended Internet Speed: 5Mbps+

Facebook Comments

Details
Presenters
Related
Comments
Recommended
  • Overview

    Join our international multidisciplinary panel of experts in exploring revolutionary approaches to treating patients with unresectable locally advanced squamous cell carcinoma of the head and neck and dinner. Through engaging presentations and discussions, the panel will address key aspects of patient management including new and emerging therapies, the clinical significance of early endpoints used in clinical trials, and future directions in treatment.

  • Program Schedule

    Times listed in Pacific Daylight Time

    6:15pm – 6:30pm   Doors Open, Registration, and Dinner
    6:30pm – 6:33pm   Welcome and Introductions
    6:33pm – 6:37pm   Overview of LA SCCHN
    6:37pm – 6:47pm   Current Landscape in LA SCCHN
    6:47pm – 6:59pm   Raising Awareness of Emerging Evidence in LA SCCHN
    6:59pm – 7:11pm    A Comprehensive Analysis of IAPs
    7:11pm – 7:20pm    Understanding Clinical Trials and Their Endpoints in LA SCCHN
    7:20pm – 7:30pm   Question and Answer Session

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Host:
    Ezra Cohen, MD, FRCPSC, FASCO
    Chief Medical Officer, Oncology
    Tempus Labs
    Professor of Medicine, Division of Hematology/Oncology
    University of California San Diego Health
    San Diego, CA, US

    Consulting Fees: Adagene, Astellas, Cidara, Eisai, Genmab, Gilboa, iTeos, Lilly, MSD, Merck, Nectin Tx, Novartis, Nykode, Pangea Therapeutics, PCI Biotech, Replimune, Roche, Soteria, Tempus, Viracta
    Employee of an ineligible company: Tempus Labs
    Ownership Interest: Kinnate Biopharma, Primmune Therapeutics
    Research: NCI

    Faculty:
    Kevin J Harrington, PhD, FRCP, FRCR, FRSB
    Professor in Biological Cancer Therapies
    The Institute of Cancer Research
    London UK

    Consulting Fees: AstraZeneca, Boehringer Ingelheim, Merck, MSD, Replimune
    Research: AstraZeneca, Boehringer Ingelheim, Replimune

    Deborah J. Wong, MD, PhD
    Associate Clinical Professor of Medicine
    David Geffen School of Medicine
    University of California, Los Angeles
    Los Angeles, CA, US

    Consulting Fees: MSD
    Research: AstraZeneca, BICARA Therapeutics, Bristol-Myers Squibb Company, FSTAR Therapeutics, Genentech, Gilead, KURA Oncology, Lilly, MSD, Pfizer, Regeneron, TopAlliance

    Reviewers/Content Planners/Authors:

    • Jorge Bacigalupo has nothing to disclose.
    • Cindy Davidson has nothing to disclose.
    • Ann Early has nothing to disclose
    • Robert Giest, MD, has nothing to disclose.
    • Andrea Mathis has nothing to disclose.
    • Tim Person has nothing to disclose.
    • Rosanne Strauss PharmD, MBA, has nothing to disclose.
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Identify the various factors that contribute to the recurrence or progression of locally advanced squamous cell carcinoma of the head and neck (SCCHN)
    • Evaluate the risks, benefits, and limitations of currently available treatment options for managing patients with locally advanced SCCHN, and develop a comprehensive management plan based on patient-specific factors
    • Discuss the mechanisms of action of agents currently under investigation for the treatment of locally advanced SCCHN alongside those of currently available treatment options, and potential implications for patient care
    • Assess the therapeutic potential and potential impact on current treatment paradigms of emerging agents being investigated for the management of locally advanced SCCHN
    • Compare the definitions, benefits, and limitations of early endpoints used in oncology trials and their relation to patient outcomes
    • Describe the evidence, rationale, and clinical significance of early endpoints used in ongoing clinical trials in locally advanced SCCHN
  • Target Audience

    This activity is designed to meet the educational needs of medical oncologists, radiation oncologists, pathologists, and other healthcare professional treating patients with head and neck cancers in the United States.

  • Accreditation and Credit Designation Statements

    In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

    Global Learning Collaborative (GLC) designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) designates this activity for 1.0 nursing contact hours. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

  • Provider(s)/Educational Partner(s)

    Prova Education designs and executes continuing education founded on evidence-based medicine, clinical need, gap analysis, learner feedback, and more. Our mission is to serve as an inventive and relevant resource for clinical content and educational interventions across a broad spectrum of specialties.

    Prova Education's methodology demonstrates a commitment to continuing medical education and the innovative assessment of its effects. Our goal is clear—to develop and deliver the very best education in the most impactful manner and to verify its results with progressive outcomes research. 

  • Commercial Support

    This activity is supported by an independent educational grant from EMD Serono, Inc. EMD Serono, Inc. is the Healthcare business of Merck KGaA, Darmstadt, Germany.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Prova Education. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to access a site outside of Prova Education you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited
    Reproduction of this material is not permitted without written permission from the copyright owner.

  • ADA Statement

    Event staff will be glad to assist you with any special needs (eg, physical, dietary, etc.). Please contact Andrea Mathis prior to the live event at amathis@glc.healthcare.

  • System Requirements

    • Supported Browsers (2 most recent versions):
      • Google Chrome for Windows, Mac OS, iOS, and Android
      • Apple Safari for Mac OS and iOS
      • Mozilla Firefox for Windows, Mac OS, iOS, and Android
      • Microsoft Edge for Windows
    • Recommended Internet Speed: 5Mbps+

Facebook Comments

Schedule20 Jul 2024